Diagnostic utility of a Ferritin-to-Procalcitonin Ratio to differentiate patients with COVID-19 from those with Bacterial Pneumonia: A multicenter study

Amal A. Gharamti, MD¹#**, Fei Mei, MD, PhD²#, Katherine C. Jankousy, MD³, Jin Huang, BSc⁴, Peter Hyson, MD³, Daniel B. Chastain, PharmD⁵, Jiawei Fan, MD², Sharmon Osae, PharmD⁵, Wayne W. Zhang, MD⁶, José G. Montoya, MD, FACP, FIDSA⁷, Kristine M. Erlandson, MD, MS⁸, Sias J. Scherger, MD⁶, Carlos Franco-Paredes, MD, MPH⁸,⁹, Andrés F. Henao-Martínez, MD⁸*, Leland Shapiro, MD⁸,¹⁰

¹Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
²Department of Vascular Surgery, Yichang Central People’s Hospital, The first College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China
³Department of Medicine, ⁴School of Medicine and ⁵Division of Infectious Diseases, University of Colorado, Anschutz Medical Center Aurora, CO, USA
⁶Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, GA, USA
⁷Division of Vascular and Endovascular Surgery, Department of Surgery, University of Washington and Puget Sound VA Health Care System, Seattle, WA, USA
⁸Co-director, Dr. Jack S. Remington Laboratory for Specialty Diagnostics, Palo Alto, California
⁹Hospital Infantil de México, Federico Gómez, México City, México
¹⁰Rocky Mountain Regional Veterans Affairs Medical Center, Aurora CO, USA

#Both authors contributed equally.

*Corresponding author: Andrés F. Henao-Martínez, MD, University of Colorado Denver 12700 E. 19th Avenue, Mail Stop B168. Aurora, CO 80045, USA; Email: andres.henoamartinez@cuanschutz.edu Tel.: +1 (720)-848-0820; fax: +1 (720)-848-0191.

ORCID number: 0000-0001-7363-8652

**Alternate Corresponding author: Amal A. Gharamti, MD, American University of Beirut, Beirut, Lebanon; E-mail: gharamti.a@gmail.com Tel.: +961-71-279876.

ORCID number: 0000-0002-6175-299X

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Author Contributions

The manuscript is seen and approved by all authors and not under consideration elsewhere. All authors contributed to the work of this report. KJ, JH, PH, JF, FM, and SO collected the clinical data. AG wrote the initial draft of the manuscript. AHM and LS assisted in the study conception and design. AHM analyzed the data. DC, WZ, JM, KE, SS, CFP, AHM, and LS edited and reviewed the final manuscript.

Summary

In this case-control multicenter study in 242 COVID-19 patients and 34 bacterial pneumonia patients, an F/P ≥ 877 was associated with an eleven times increased odds of COVID-19, with a positive predictive value for separating COVID-19 from bacterial pneumonia of 93%.
Abstract

**Background** There is an urgent need for accurate, rapid, inexpensive biomarkers that can differentiate COVID-19 from bacterial pneumonia. We assess the role of the ferritin-to-procalcitonin (F/P) ratio to classify pneumonia cases into those due to COVID-19 or due to bacterial pathogens.

**Methods** This multicenter case-control study compared patients with either COVID-19 and bacterial pneumonia, admitted between March 1 and May 31, 2020. Patients with COVID-19 and bacterial pneumonia co-infection were excluded. The F/P in patients with COVID-19 or with bacterial pneumonia were compared. Receiver operating characteristic analysis determined the sensitivity and specificity of various cut-off F/P values for COVID-19 versus bacterial pneumonia.

**Results** A total of 242 COVID-19 pneumonia cases and 34 bacterial pneumonia controls were included. Patients with COVID-19 pneumonia had a lower mean age (57.11 vs 64.4 years, p=0.02) and a higher BMI (30.74 vs 27.15 kg/m², p=0.02) compared to patients with bacterial pneumonia. Cases and controls had a similar proportion of women (47% vs 53%, p=0.5) and COVID-19 patients had a higher prevalence of diabetes mellitus (32.6% vs 12%, p=0.01). The median F/P was significantly higher in patients with COVID-19 (4037.5) compared to the F/P in bacterial pneumonia (802, p<0.001). An F/P ≥ 877 used to diagnose COVID-19 resulted in a sensitivity of 85% and a specificity of 56%, with a positive predictive value of 93.2%, and a likelihood ratio of 1.92. In multivariable analyses, an F/P ≥ 877 was associated with greater odds of identifying a COVID-19 case (OR: 11.27, CI: 4-31.2, p<0.001).

**Conclusion** An F/P ≥ 877 increases the likelihood of COVID-19 pneumonia compared to bacterial pneumonia.

Keywords: COVID-19; Ferritin; Procalcitonin; Pneumonia; SARS-CoV-2
Introduction

The Coronavirus Disease 2019 (COVID-19) was declared a global pandemic by the World Health Organization on March 11, 2020. It is challenging to differentiate COVID-19 pneumonia from bacterial pneumonia at the time of clinical presentation. The clinical similarity between COVID-19 and bacterial pneumonia has resulted in concomitant use of antibiotics in up to 100% of COVID-19 patients. In 4,267 COVID-19 patients in New York City, co-infections were diagnosed in 3.6% of patients (mostly bacterial), yet antibiotics were given in 71% of these patients. This mismatch between true co-infection and clinically presumed co-infection at the time of presentation emphasizes the difficulty in separating COVID-19 from bacterial infection. Early diagnosis enables expeditious use of appropriate antiviral or antibacterial treatments, minimizes adverse effects and costs associated with empirical therapies targeting both viral and bacterial infections, and facilitates infection control measures designed to prevent COVID-19 transmission. Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) used to diagnose COVID-19 typically requires at least 24 hours to return and can take more than 72 hours in low-resource settings. The clinical utility of other rapid antigen or molecular-based tests has not been established. Thus, investigation of biomarkers has emerged as an important area of study in efforts to discriminate COVID-19 pneumonia from bacterial pneumonia.

Several laboratory markers have been studied for diagnosing COVID-19 and for assessing the severity of COVID-19 at the time of clinical presentation. We created the F/P index using a model-based approach to biomarker development. A scientific model is a simplified description of a phenomenon (disease) that represents the disease to learn about the mechanism of disease production (how it arises) and suggests treatments. A common example of this activity is the use of animal models to explore pathogenesis and therapy. In our model, we use simple components that include respiratory cells and the pathogen SARS-
CoV-2. The model specifies interactions between pathogen and respiratory cells derived from the literature. In this model, SARS-CoV-2 produces disease by virion replication and obligate cytolysis in the respiratory epithelium that results in respiratory dysfunction. The magnitude of virus replication and cytolysis reflects disease severity. There is also an associated inhibition of systemic inflammation caused by-products of viral replication. In contrast, in bacterial pneumonia, most organisms do not require intracellular replication and cytolysis and thus produce less respiratory cell destruction compared to SARS-CoV-2. PCT is a marker of systemic inflammation that is consistently higher in bacterial infections compared to viral infections. This model focuses on significant differences in the mechanism of pathogen replication and host inflammation during infection, and we sought biomarkers that best represented these two model components. We restricted candidate biomarkers to those widely available, rapidly obtainable, and inexpensive. This model-based approach led us to focus on procalcitonin (PCT) and the iron-storage protein ferritin.

Our model predicts the ratio of circulating ferritin level (ng/ml) and PCT (ng/ml), called the ferritin/procalcitonin ratio (F/P), would be higher in COVID-19 pneumonia than in bacterial pneumonia.

Methods

Ethics statement:

This investigation was approved by the Colorado Multiple Institutional Review Board (COMIRB) at the University of Colorado Anschutz Medical Campus (UCHealth), the Institutional Review Board (IRB) at Phoebe Putney Memorial Hospital in Albany, Georgia (USA), and the IRB at Yichang Central People’s Hospital of China Three Gorges University. Clinical data were obtained under a protocol reviewed and approved by IRBs and ethics
committees at UCHealth (COMIRB Protocol 20-0690), Phoebe Putney Memorial Hospital (PROJECT00002679), and Yichang Central People’s Hospital (HEC-KYJJ-2020-026-01).

Patients and data collection:

COVID-19 patients admitted to UCHealth, Yichang Central People’s Hospital, or Phoebe Putney Memorial Hospital from March 1 to May 31, 2020, were considered for inclusion. These sites were included based on collaborative efforts and the adoption of similar diagnostic criteria. The diagnosis of COVID-19 pneumonia was established by positive RT-PCR, clinical signs and symptoms, and imaging findings suggesting pneumonia. Exclusion criteria included patients younger than 18 years, pregnancy, death on admission, missing baseline data, or transfer to another hospital. We excluded patients with concurrent COVID-19 and bacterial pneumonia at the time of hospital presentation. Based on our hypothesis of cytolysis-mediated lung injury, we anticipated the co-infected patients with COVID-19 and bacterial pneumonia to also have an elevated P/F ratio, making differentiation more difficult. Patients diagnosed with bacterial pneumonia in the absence of COVID-19 served as controls. Bacterial pneumonia was diagnosed by clinical signs and symptoms of pneumonia, radiologic evidence of pneumonia on chest imaging, microbiologic documentation of a bacterial pathogen, and a negative COVID-19 PCR test.

Electronic medical records were manually abstracted for clinical and laboratory variables. At UCHealth and Phoebe Putney Memorial Hospital, data were retrospectively collected and stored in RedCap (electronic capture tools). At Yichang Central People’s Hospital, data were transferred manually into an excel file. The following data were collected: gender, race/ethnicity, age, weight, and body mass index (BMI), oxygen saturation in the Emergency Department, recorded pre-existing medical conditions including diabetes mellitus (DM) and hypertension (HTN), and laboratory results including lactate.
dehydrogenase (LDH), ferritin, and PCT. LDH level was extracted since it is an intracellular enzyme that is elevated in the setting of organ damage. Based on our hypothesis that SARS-CoV-2 causes damage by cytolysic lysis, we predict LDH to be more elevated in COVID-19 patients compared to bacterial pneumonia patients.

Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)

At UCHealth, upper respiratory tract samples were subjected to reverse transcription PCR amplification for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, Roche Cobas 6800 EUA, Roche Diagnostics Corporation, Indianapolis, Indiana).

At Phoebe Putney Memorial Hospital, several PCR platforms were used, including tests employed at Labcorp, Quest, and use of the Cepheid Xpert® Xpress SARS-CoV-2 (Cepheid, Sunnyvale, California, USA).

At Yichang Central People’s Hospital, RT-PCR was performed using the Detection Kit for SARS-CoV-2 RNA (PCR-Fluorescence Probing, Da An Gene Co., Ltd. of Sun Yat-sen University, Guandong, China) to detect SARS-CoV-2 virus nucleic acid.

Statistical analysis:

Statistical analyses were performed using STATA software, version 12.1 (StataCorp, College Station, Texas, USA). Continuous variables were summarized using means (± standard deviations) or medians (± interquartile ranges). Frequencies (percent) were used to describe categorical variables. Dichotomous outcomes were compared using chi-square analysis. The Fisher exact test was used to compare nominal independent variables, and a t-test or Mann-Whitney U test was employed for interval independent variables. Co-linear variables or variables with missing significant data were excluded. We excluded from analysis 102 cases with COVID-19 and bacterial pneumonia co-infections. We compared F/P
in patients diagnosed with COVID-19 to F/P in patients with bacterial pneumonia using a logistic regression controlling for age, sex, BMI, DM, HTN, and cohort site. A receiver operating characteristic (ROC) curve that compared true positive rates (sensitivity) to false-positive rates (1-specificity) for various F/P values. The optimal F/P value that separated patients with COVID-19 pneumonia from patients with bacterial pneumonia was determined. Statistical significance was set at the 0.05 alpha level.

We analyzed F/P in the UCHealth cohort and separately analyzed F/P in the other two hospitals combined. An ROC curve was constructed for F/P in UCHealth patients and separately in the two hospital cohorts combined, and areas under the ROC curves calculated.

Data access

The corresponding author had full access to data in the study and had final responsibility for the decision to submit the manuscript for publication. The datasets used in the current study are available from the corresponding author on a reasonable request.

Results

Clinical characteristics and laboratory data in the three participating sites

Table 1 shows the clinical characteristics and laboratory data obtained in study subjects in each participating hospital. COVID-19 patients in the UCHealth cohort were Hispanic (43.2%), followed by African American (21.4%), White (18.2%), Asian (10%), and others (7.2%). In the Putney Memorial cohort, most patients were African American (77.4%), followed by white (19.4%) and Hispanic (3.2%). In Yichang Central People’s Hospital, all patients were Asian (100%). DM and HTN were most prevalent in the Phoebe Putney Memorial Hospital group. A significantly larger percentage of patients from UCHealth and Phoebe Putney Memorial Hospitals were treated with intubation and mechanical ventilation compared to patients from the Yichang Central People’s Hospital. The median ferritin and
procalscitonin levels were higher in Phoebe Putney Memorial Hospital’s patients compared to patients at UCH Health and Yichang Central People’s Hospital. The median F/P was lower in the UCH Health cohort compared to the cohorts from Phoebe Putney Memorial Hospital and Yichang Central People’s Hospital.

Ferritin, Procalcitonin, and F/P in the Derivation Cohort (UCH Health)

A total of 192 patients with COVID-19 and 17 patients with bacterial pneumonia were diagnosed at UCH Health. The median F/P in the UCH Health group was significantly higher in patients with COVID-19 pneumonia than in the bacterial pneumonia group (3195 vs 860, respectively, p<0.001, Figure 1A). An F/P cut-off point of ≥ 1250 generated a sensitivity of 78% and a specificity of 59% to separate COVID-19 cases from bacterial pneumonia cases, with an AUC of 0.78 (Figure 2A). Adjusted for age, gender, BMI, DM, and HTN, an F/P ≥ 1250 associates with COVID-19 (OR: 4.9, CI: 1.5-16.1, p=0.009).

Ferritin, Procalcitonin and F/P in the Validation Cohort

The F/P was then assessed for consistency using data from the Putney Memorial group and Yichang Central People’s Hospital group as validation cohorts. A total of 50 patients with COVID-19 and 17 patients with bacterial pneumonia were diagnosed at Putney Memorial and Yichang Central People’s Hospitals. The median F/P in these cohorts was significantly higher in patients with COVID-19 pneumonia than in the bacterial pneumonia group (7461.1 vs 414, respectively, p<0.001). A cut-off F/P of 1250 would correctly classify 68% of the COVID-19 cases for patients in the Putney Memorial and Yichang Central People’s Hospital cohorts combined. With a cut-off of 877, this percentage increases to 73%. The ROC curve is shown in figure 2B, with an AUC of 0.63.
Characteristics of patients with COVID-19 and patients with bacterial pneumonia

Our combined cohort comprised 242 hospitalized patients diagnosed with COVID-19 and 34 hospitalized patients diagnosed with bacterial pneumonia in the three participating hospitals combined, and patient characteristics are shown in Table 2 (none of these patients were co-infected). Patients with COVID-19 pneumonia were significantly younger and had a significantly higher mean BMI than patients with bacterial pneumonia. Both groups had similar proportions of women. DM was significantly more common in the COVID-19 group compared to the group with bacterial pneumonia. Mean oxygen saturation in COVID-19 patients upon presentation in the Emergency Department was lower than the mean in patients with bacterial pneumonia, although the difference was not statistically significant. Patients with COVID-19 pneumonia were more likely to have a course complicated by intubation compared to patients with bacterial pneumonia, without reaching statistical significance.

*Streptococcus pneumoniae*, *Escherichia coli*, *Serratia marcescens*, and *Pseudomonas aeruginosa* were among the bacteria isolated in some of the controls included in the study. There was no predominant type of bacteria.

The median ferritin level was significantly higher in the COVID-19 pneumonia group compared to the bacterial pneumonia group. Patients with bacterial pneumonia had a significantly higher median procalcitonin level compared to patients with COVID-19 pneumonia. The median F/P was significantly higher in patients with COVID-19 (Table 2 and Figure 1B).

Patients with COVID-19/bacterial pneumonia co-infection had a median F/P ratio of 5018, compared to 4037.5 (p=0.58) among COVID-19 patients without co-existing bacterial pneumonia.
Predictors of COVID-19 Pneumonia

Adjusting for age, gender, BMI, DM, HTN, and admission hospital, an F/P ≥ 877 was associated with an eleven-fold increased odds of COVID-19 compared to bacterial pneumonia (OR=11.27; CI [4.07-31.20]; p<0.001) (Table 3).

Discussion

In this retrospective multicenter study, an F/P cut-off point of ≥ 877 generated a sensitivity of 85% and a specificity of 56% to differentiate COVID-19 pneumonia from bacterial pneumonia. We found similar F/P performance in patients from UCHealth and the validation cohort, suggesting the diagnostic value of the F/P generalizes to other patient populations.

The F/P may have substantial clinical applicability. Circulating ferritin and procalcitonin levels can be easily obtained on admission blood testing, with results available within minutes to a few hours and providing real-time information on whether patients are more likely to have COVID-19 compared to bacterial pneumonia. This information may guide antimicrobial administration, patient isolation until the diagnosis of COVID-19 is confirmed, and specific treatment considerations. Unnecessary antimicrobial therapy and associated harms may be reduced. The prevalence of bacterial co-infections among patients with COVID-19 in our study was 15.4%, and we excluded these patients from this report. In a large cohort of 1705 COVID-19 patients, the prevalence of community-onset bacterial co-infections was only 3.5%. Despite the low rate of bacterial co-infections, the rate of empiric antimicrobial use was 56.6%. In another cohort of 4,267 COVID-19 patients in New York City, co-infections were diagnosed in 3.6% of the cases. The larger percentage of co-infected patients in our study in the total patient group reflects patient population variability. The disproportionately high rate of antimicrobial use in COVID-19 patients despite the low
prevalence of co-infections is uniformly reported across studies.\textsuperscript{13} We realize the sensitivity of F/P in our cohort is low to accurately rule out SARS-CoV-2 infection. We believe this tool is complementary to clinical judgement and other laboratory tests that help in the distinction between COVID-19 and bacterial infection. Its utility might be best in low-resource settings or in situations where the results of the PCR are delayed. It is also best used in settings where the PCR is falsely negative and the clinical suspicion for COVID-19 is high. Although not addressed in this report, we are evaluating F/P for use in discerning co-infected patients from patients infected with COVID-19 alone.

There is limited data available on serum ferritin levels in swine H1N1 and avian H5N1 infected patients to tell whether this ratio can be applied to this other viral infection\textsuperscript{14}. A recent study\textsuperscript{15} showed that hyperferritinemia is associated with poor outcomes in influenza A infection. Since lung injury in influenza is mediated by cytolysis—in a similar manner as with SARS-CoV-2—we hypothesize the ratio may have some utility in Influenza pneumonia as well.

Significant cytolysis caused by SARS-CoV-2 replication is suggested by \textit{in vitro} observations in the closely related virus SARS-CoV, where prodigious viral replication within human primary ciliated respiratory epithelial cells caused cytopathy and cell shedding from tissues.\textsuperscript{16} Ferritin was chosen as the marker for cytolysis during viral infection. Ferritin stores iron within cells and protects cell components from iron-induced free radical generation.\textsuperscript{17} Circulating ferritin is often mischaracterized as an acute-phase reactant and likely originates from cell injury or cytolysis. Observations supporting this concept include the absence of a mechanism for cell secretion of ferritin.\textsuperscript{18} Serum ferritin levels are unaffected by elevated plasma levels of acute-phase inducing cytokines tumor necrosis factor-alpha (TNF) or Interleukin-6 (IL-6) in healthy volunteers. In contrast, there is a correlation between serum ferritin levels and circulating cell-free DNA (cfDNA) in
hemodialysis patients. Since cell-free DNA is a cytology footprint, this report indicates that cytolyis is mirrored by elevated ferritin. A significant role for cytolysis during COVID-19 is indicated by the presence of elevated cell-free DNA in COVID-19, and increased COVID-19 cfDNA associates with increased disease severity. The association of viral infection of cells with cytolysis and liberation of intracellular ferritin into the blood is consistent with the substantial elevation of blood ferritin reported in COVID-19 patients. Since the exact source of circulating cfDNA and ferritin during COVID-19 is unknown, lysis of non-respiratory epithelial cells may be additional sources for these cytolysis products. Regardless of the source, the magnitude of total cytolysis in COVID-19 patients likely reflects total viral replication activity and indicates disease severity. In contrast to COVID-19, bacterial pathogenesis does not necessitate host cell lysis since most typical bacterial pneumonia pathogens do not require intracellular invasion to replicate. We believe it is useful to think of circulating ferritin as a biomarker indicating cytolysis and suggest an analogy with circulating levels of cardiac isoenzymes (often Troponin proteins) as indicators of cardiomyocyte lysis or damage.

TNF and IL-1ß (IL-1) are prototype pro-inflammatory mediators involved in the host immune response. TNF levels are significantly lower in patients with COVID-19 and ARDS compared to patients with bacterial septic shock with ARDS, suggesting a less robust inflammatory response in COVID-19 compared to bacterial infections. Procalcitonin (PCT) is an established marker of inflammation and has been shown to increase in response to TNF and IL-1. Moreover, PCT synthesis is suppressed by interferon-gamma (IFN), which is produced in response to viral infections and may participate in lowering PCT levels during viral infections. A review comparing PCT levels in viral and bacterial pneumonia in pediatric patients showed lower PCT concentrations in viral pneumonia. For adult pneumonia, a systematic review and meta-analysis revealed circulating PCT >0.05 µg/mL.
used to diagnose bacterial infection is associated with sensitivity and specificity of 0.55 and 0.76 respectively (considered a moderate degree of discrimination). Considered together, it appears viral pneumonia—like COVID-19—produces lower systemic inflammation compared to bacterial pneumonia, and this is reflected in lower PCT concentrations in viral pneumonia. Given its widespread availability, lower cost, and fast turnaround time compared with levels of TNF or IL-1, we chose PCT as a surrogate marker of inflammation.

This study has several limitations. Proper use of F/P requires obtaining ferritin and PCT simultaneously as soon as possible after clinical presentation. However, our data included the first available levels of ferritin and PCT, and these levels were often not obtained simultaneously or immediately after initial presentation. The diagnostic characteristics of F/P may improve with the use of early and simultaneous acquisition of ferritin and PCT. Another limitation is the low specificity of this metric in either including or excluding bacterial pneumonia. Therefore, it might not be helpful in the decision-making of initiating or withholding antibiotics. Our study is likely underpowered to detect differences between COVID-19 pneumonia cases and bacterial pneumonia controls since we included only controls with microbiologic documentation of a bacterial infection, whereas most cases of community-acquired pneumonia do not have a positive bacterial culture. Additionally, without a matching strategy due to the relatively small number of patients, the sample size might be underpowered, limiting the reliability of the results presented. Our total patient cohort from all 3 hospitals included only 34 patients with bacterial pneumonia, and more bacterial pneumonia may provide a more accurate estimate of the utility of F/P. The F/P ratio is also dichotomized using ROC inflection points, and this dichotomization likely led to decreased statistical power. The retrospective study design makes it susceptible to several biases, and the applicability of F/P to other patient populations is uncertain. Due to limitations of available data, we were unable to assess F/P association with important
outcomes like mortality, ICU stay, and mechanical ventilation. Although we adjusted for several confounders, there may be confounders unaccounted for in our analysis. Furthermore, F/P overlap occurred at low values for F/P (Fig 1), and our model predicts this is likely due to COVID-19 patients with mild disease. Low F/P in COVID-19 likely associates with smaller amounts of cytolysis and increased inflammation, a combination associated with a bacterial infection. It may therefore be difficult to separate mild COVID-19 cases from cases of bacterial pneumonia. If our model accurately reflects disease mechanism, serial calculation of F/P could be used as a tool to quantify the severity of infection over time and may predict clinical outcomes like mortality. This report introduces this novel index, and it is our belief F/P will perform better when ferritin and PCT are obtained as soon as possible after hospital presentation.

In summary, the novel F/P may assist with the early identification of COVID-19 patients. It is best used in combination with clinical judgment and other laboratory tools, where it could assist in the decision-making to withhold antibiotics in non-critical cases till the results of PCR and other laboratory markers and cultures are out. Further studies should evaluate its potential to quantify COVID-19 severity and prognosis.
**Funding:** Dr. Leland Shapiro is supported by The Emily Foundation. Dr. Erlandson is funded by the National Institute on Aging (AG054366-05S1) and has received research and consultative funds from Gilead Sciences (paid to the University of Colorado).

**Acknowledgements:** We acknowledge the support of the University of Colorado medical students who contributed significantly to the chart abstraction.

**Conflict of Interest:** None declared.

**Patient Consent Statement:** The design of the study has been approved by the Institutional Review Board at the University of Colorado Anschutz Medical Campus, Phoebe Putney Memorial Hospital, and Yichang Central People’s Hospital. Due to the retrospective nature of this study, the need for patient consent was waived.
Table 1: Characteristics of patients included at the three participating sites

|                                | UCHealth (N=209) | Phoebe Putney Memorial Hospital (N=31) | Yichang Central People’s Hospital (N=36) |
|--------------------------------|------------------|----------------------------------------|----------------------------------------|
| **Cohort, n (%)**              |                  |                                        |                                        |
| Cases                          | 192 (92)         | 27 (87)                                | 23 (64)                                |
| Controls                       | 17 (8)           | 4 (13)                                 | 13 (36)                                |
| **Race (%)**                   |                  |                                        |                                        |
| African                        | 21.4             | 77.4                                   | 0                                      |
| Hispanic                       | 18.2             | 19.4                                   | 0                                      |
| Other                          | 7.3              | 0                                      | 0                                      |
| **Age, years [mean (SD)]**     | 56.77 (18.3)     | 62 (13.4)                              | 62.08 (15.3)                           |
| **BMI, kg/m^2 [mean (SD)]**    | 30.57 (7.1)      | 36 (12)                                | 23.5 (2.8)                             |
| **Female Gender, n (%)**       | 101 (48)         | 19 (61)                                | 11 (31)                                |
| **Comorbidities, n(%)**        |                  |                                        |                                        |
| Hypertension                   | 95 (46)          | 21 (68)                                | 18 (50)                                |
| Diabetes                       | 64 (31)          | 11 (36)                                | 8 (22)                                 |
| **Intubated, n (%)**           | 32 (15.3)        | 9 (29)                                 | 4 (11)                                 |
| **LDH, IU/L (M [IQR])**        | 324.5 [261-429.5]| 379 [345-562]                          | 248 [191-327]                          |
| **Procalcitonin, ng/ml (M [IQR])** | 0.12 [0.05-0.24] | 0.18 [0.08-0.72]                       | 0.1 [0.05-0.24]                        |
| **Ferritin, ng/ml (M [IQR])**  | 353 [168-608]    | 786.4 [385.10-1059]                    | 543.8 [285.15-1306.18]                 |
| **F/P (M [IQR])**              | 3088.46 [1231.82-6600] | 6205.56 [877.75-12961.11] | 6829.08 [2491.63-9658.67] |
| **F/P ≥ 877, n (%)**           | 166 (79)         | 24 (77)                                | 30 (83)                                |

SD: standard deviation; M [IQR]: Median [Inter-quartile range]; LDH: lactate dehydrogenase; F/P: Ferritin/Procalcitonin ratio
| Characteristic                        | COVID-19 Pneumonia (n=242) | Bacterial Pneumonia (n=34) | P-value |
|--------------------------------------|----------------------------|---------------------------|---------|
| Age, years [mean (SD)]              | 57.11 (17.36)              | 64.4 (17.72)              | 0.02    |
| BMI, kg/m² [mean (SD)]              | 30.74 (8.10)               | 27.15 (7.98)              | 0.02    |
| Female Gender, n (%)                | 113 (47)                   | 18 (53)                   | 0.50    |
| Comorbidities n (%)                 |                            |                           |         |
| Hypertension                        | 117 (48.3)                 | 17 (50)                   | 0.86    |
| Diabetes Mellitus                   | 79 (32.6)                  | 4 (12)                    | 0.01    |
| Intubated, n (%)                    | 42 (17.36)                 | 3 (9)                     | 0.98    |
| ED O₂ Saturation [mean (SD)]        | 89.6 (7.87)                | 95.8 (4.21)               | 0.08    |
| LDH, IU/L (M [IQR])                 | 324.5 [258.5-423]          | 262 [197-466.5]           | 0.15    |
| Procalcitonin, ng/ml (M [IQR])      | 0.11 [0.05-0.22]           | 0.33 [0.11-1.26]          | <0.001  |
| Ferritin, ng/ml (M [IQR])           | 427 [220.5-873]            | 287.5 [124-468]           | 0.01    |
| F/P                                  | 4037.5 [1508.86-8118.89]   | 802.09 [128.57-2597.81]   | <0.001  |
| F/P ≥ 877                            | 205 (84.7)                 | 15 (44.1)                 | <0.001  |
| F/P ≥ 1250                           | 192 (79.34)                | 15 (44.1)                 | <0.001  |

SD: standard deviation; M [IQR]: Median [Inter-quartile range]; LDH: lactate dehydrogenase; F/P: Ferritin/Procalcitonin ratio
Table 3: Predictors of COVID-19 pneumonia in multivariate logistic regression

| Parameter     | OR (95% CI)      | P-value |
|---------------|------------------|---------|
| F/P ≥ 877     | 11.27 (4.07-31.20) | <0.001  |
| Age           | 0.98 (0.95-1.01)  | 0.16    |
| Gender        | 0.36 (0.14-0.98)  | 0.05    |
| BMI           | 1.06 (0.99-1.13)  | 0.07    |
| DM Type 2     | 2.66 (0.78-9.04)  | 0.12    |
| Hypertension  | 0.47 (0.16-1.38)  | 0.17    |
| Hospital      | 0.45 (0.25-0.80)  | 0.006   |
Figure 1A: Ferritin to Procalcitonin Ratios of patients with COVID-19 pneumonia and patients with Bacterial Pneumonia (controls) at UCHealth. Figure 1B: Ferritin to Procalcitonin Ratios in patients with COVID-19 pneumonia and patients with Bacterial Pneumonia (controls) in the three cohorts combined.
Figure 2A: Receiver Operating Characteristic Analysis of Ferritin to Procalcitonin Ratio Cut-off Values Predicting COVID-19 Diagnosis for UCHealth. Figure 2B: Receiver Operating Characteristic Analysis of Ferritin to Procalcitonin Ratio Cut-off Values Predicting COVID-19 Diagnosis in the Putney Memorial and Yichang Central People’s Hospital Cohorts.
References

1. Organization WH. 2020; https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline/.

2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* Feb 15 2020;395(10223):497-506.

3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* Feb 15 2020;395(10223):507-513.

4. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA.* Aug 4 2020;324(5):460-470.

5. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. *Infect Control Hosp Epidemiol.* Jul 24 2020:1-5.

6. Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev.* Aug 26 2020;8:CD013705.

7. Bailer-Jones DM. *Scientific models in philosophy of science.* University of Pittsburgh Pre; 2009.

8. Gerlee P, Lundh T. Scientific models. *Red Atoms, White Lies and Black Boxes in a Yellow Book.* Switzerland: Springer. 2016.

9. Schubert K, Karoussis ED, Jomaa A, et al. SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. *Nat Struct Mol Biol.* Oct 2020;27(10):959-966.

10. Schubert K, Karousis ED, Jomaa A, et al. Author Correction: SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. *Nat Struct Mol Biol.* Nov 2020;27(11):1094.
11. Lubell Y, Blacksell SD, Dunachie S, et al. Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in Southeast Asia. *BMC Infect Dis.* Nov 11 2015;15:511.

12. Vaughn VM, Gandhi T, Petty LA, et al. Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study. *Clinical Infectious Diseases.* 2020.

13. Rawson TM, Moore LS, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. *Clinical Infectious Diseases.* 2020.

14. Kappert K, Jahić A, Tauber R. Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases. *Biomarkers.* 2020;1-10.

15. Lalueza A, Ayuso B, Arrieta E, et al. Elevation of serum ferritin levels for predicting a poor outcome in hospitalized patients with influenza infection. *Clinical Microbiology and Infection.* 2020;26(11):1557. e1559-1557. e1515.

16. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, Pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. *J Virol.* Dec 2005;79(24):15511-15524.

17. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. *Blood reviews.* 2009;23(3):95-104.

18. Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. *Metallomics.* 2014;6(4):748-773.

19. Cichota LC, Bochi GV, Tatsch E, et al. Circulating Double-Stranded DNA in Plasma of Hemodialysis Patients and its Association with Iron Stores. *Clin Lab.* 2015;61(8):985-990.

20. Butt AN, Swaminathan R. Overview of circulating nucleic acids in plasma/serum. *Ann N Y Acad Sci.* Aug 2008;1137:236-242.

21. Cheng AP, Cheng MP, Gu W, et al. Cell-Free DNA in Blood Reveals Significant Cell, Tissue and Organ Specific injury and Predicts COVID-19 Severity. *medRxiv.* 2020.
22. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* Jul 1 2020;180(7):934-943.

23. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA.* May 26 2020;323(20):2052-2059.

24. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions. *JAMA.* Sep 3 2020.

25. Gilbert DN. Neglected Variables in the Interpretation of Serum Procalcitonin Levels in Patients With Septic Shock. *J Infect Dis.* Jul 21 2020;222(Supplement_2):S96-S102.

26. Thomas J, Pociute A, Kevalas R, Malinauskas M, Jankauskaite L. Blood biomarkers differentiating viral versus bacterial pneumonia aetiology: a literature review. *Ital J Pediatr.* Jan 9 2020;46(1):4.

27. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. *Clin Infect Dis.* Jan 16 2020;70(3):538-542.